Tenax Therapeutics logo
Tenax Therapeutics TENX
$ 1.83 0.54%
report update icon

Quarterly report 2026-Q2
added 07-31-2026

Tenax Therapeutics Deferred Revenue | TENX

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.
Features of the metric
  • Sources of future cash inflows
    A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
  • Assessment of operational stability
    Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
  • Risks and obligations
    Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
  • Analysis of liquidity and cash flow
    Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
  • Impact on company valuation
    In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Tenax Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 1967
- - - - - - - - - - - 125 K 185 K - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
185 K 125 K 155 K

Deferred Revenue of other stocks in the Biotechnology industry

Issuer Deferred Revenue Price % 24h Market Cap Country
AbCellera Biologics AbCellera Biologics
ABCL
13.5 M $ 11.41 2.15 % $ 3.41 B canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
3.94 M $ 5.53 6.02 % $ 678 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
834 K $ 1.09 3.74 % $ 139 M schweizSchweiz
Amryt Pharma plc Amryt Pharma plc
AMYT
23 M - - $ 621 M britainBritain
Chimerix Chimerix
CMRX
1.54 M - - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
2.75 M - - $ 401 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
143 K $ 8.61 0.16 % $ 2.05 B usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
333 K - - $ 1.41 B canadaCanada
Genocea Biosciences Genocea Biosciences
GNCA
1.7 M - -15.0 % $ 3.04 M usaUSA
Gritstone Oncology Gritstone Oncology
GRTS
2.35 M - 0.42 % $ 213 M usaUSA
G1 Therapeutics G1 Therapeutics
GTHX
620 K - - $ 370 M usaUSA
Harpoon Therapeutics Harpoon Therapeutics
HARP
30.9 M - - $ 763 M usaUSA
Humanigen Humanigen
HGEN
883 K - -81.12 % $ 4.28 M usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
4.76 M - -6.92 % $ 79.4 M usaUSA
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
1.62 M - - $ 643 M usaUSA
IMV IMV
IMV
139 K - - $ 13.1 M canadaCanada
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
1.67 M - - $ 13.6 B usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
95 K - - $ 2.6 B usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
828 K - -3.69 % $ 12.4 M usaUSA
Kronos Bio Kronos Bio
KRON
1.86 M - 1.49 % $ 50.8 M usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
2.85 M - - $ 154 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
10.6 M - - $ 229 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
56 K - - $ 35.3 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
36.2 M - - $ 216 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
824 K - - $ 3.3 B usaUSA
9 Meters Biopharma 9 Meters Biopharma
NMTR
125 K - -42.97 % $ 1.05 M usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
2.51 M - -19.68 % $ 18.4 M canadaCanada
Oncternal Therapeutics Oncternal Therapeutics
ONCT
1.63 M - -24.12 % $ 1.56 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
16.6 K - - $ 109 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
959 K - 1.02 % $ 90.8 M britainBritain